Search Results

Xihuang pill suppresses breast cancer malignancy by inhibiting TGF-β signaling and acquires chemotherapy benefits.

• Authors : Hong, Weimin^1,2 (AUTHOR); Tang, Hongchao^1,2 (AUTHOR); Wang, Danhong^1,2,3 (AUTHOR)

Subjects: *CHINESE medicine; *BIOLOGICAL models; *EPITHELIAL-mesenchymal transition

• Source: Journal of Ethnopharmacology. Jan2025:Part 3, Vol. 337, pN.PAG-N.PAG. 1p.

Record details

A translational study for biomarker identification of PEP-010, a pro-apoptotic peptide restoring apoptosis in cancer models.

• Authors : Germini, D.¹ (AUTHOR) ; Farhat, R.¹ (AUTHOR); Dadon, L.¹ (AUTHOR)

Subjects: *PEPTIDES; *BREAST cancer; *TUMOR markers

• Source: BBA: Molecular Basis of Disease. Jan2025, Vol. 1871 Issue 1, pN.PAG-N.PAG. 1p.

Record details

An annotated biobank of triple negative breast cancer patient-derived xenografts featuring treatment-naive and longitudinal samples throughout neoadjuvant chemotherapy.

• Source: Women's Health Weekly; 12/20/2024, p133-133, 1p

Record details

Findings in Breast Cancer Reported from Second Hospital of Shandong University (Targeting PRMT5 through PROTAC for the treatment of triple-negative breast cancer).

• Source: Women's Health Weekly; 12/20/2024, p415-415, 1p

Record details

Modeling development of breast cancer: from tumor microenvironment to preclinical applications.

• Authors : Tang, Ruizhi; Liu, Xi-Qiu

• Source: Frontiers in Pharmacology; 2024, p1-9, 9p

Record details

IDEAYA Announces Development Candidate Nomination of IDE251, a Potential First-in-Class KAT6/7 Dual Inhibitor Targeting 8p11 Amplification Tumors in Breast and Lung Cancers

• Source: PR Newswire. December 16, 2024

Record details

Correction: Long non-coding RNA LINC02163 accelerates malignant tumor behaviors in breast cancer by regulating the microRNA-511-3p/HMGA2 axis as a competing endogenous RNA.

Subjects: LINCRNA; SURGERY; GENE expression

• Source: Oncology Research; 2024, Vol. 32 Issue 9, p1517-1522, 6p

Record details

Broadening horizons: the multifaceted role of ferroptosis in breast cancer.

• Authors : Ge, Anqi; Xiang, Wang; Li, Yan

• Source: Frontiers in Immunology; 2024, p1-20, 20p

Record details

Ensem Therapeutics To Present Preclinical Data for Potential Best-in-Class Allosteric Pan-Mutant-Selective PI3Ka Inhibitor and Degrader at San Antonio Breast Cancer Symposium.

• Source: Plus Company Updates. 2024.

Record details

Ensem Therapeutics To Present Preclinical Data for Potential Best-in-Class Allosteric Pan-Mutant-Selective PI3K Inhibitor and Degrader at San Antonio Breast Cancer Symposium.

• Source: Business Wire. 2024.

Record details